KR20240068070A - 변형된 인터루킨 p40 서브유닛 단백질 및 이의 사용 방법 - Google Patents

변형된 인터루킨 p40 서브유닛 단백질 및 이의 사용 방법 Download PDF

Info

Publication number
KR20240068070A
KR20240068070A KR1020247014070A KR20247014070A KR20240068070A KR 20240068070 A KR20240068070 A KR 20240068070A KR 1020247014070 A KR1020247014070 A KR 1020247014070A KR 20247014070 A KR20247014070 A KR 20247014070A KR 20240068070 A KR20240068070 A KR 20240068070A
Authority
KR
South Korea
Prior art keywords
domain
amino acid
modified
fusion protein
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247014070A
Other languages
English (en)
Korean (ko)
Inventor
라이언 블랙러
토마스 스프레터 본 크로이덴슈타인
Original Assignee
자임워크스 비씨 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 자임워크스 비씨 인코포레이티드 filed Critical 자임워크스 비씨 인코포레이티드
Publication of KR20240068070A publication Critical patent/KR20240068070A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10—Design of libraries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247014070A 2021-09-29 2022-09-29 변형된 인터루킨 p40 서브유닛 단백질 및 이의 사용 방법 Pending KR20240068070A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163249685P 2021-09-29 2021-09-29
US63/249,685 2021-09-29
PCT/CA2022/051445 WO2023050006A1 (en) 2021-09-29 2022-09-29 Modified interleukin p40 subunit proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20240068070A true KR20240068070A (ko) 2024-05-17

Family

ID=85780291

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247014070A Pending KR20240068070A (ko) 2021-09-29 2022-09-29 변형된 인터루킨 p40 서브유닛 단백질 및 이의 사용 방법

Country Status (9)

Country Link
US (1) US20240228567A1 (cg-RX-API-DMAC7.html)
EP (1) EP4408870A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024535925A (cg-RX-API-DMAC7.html)
KR (1) KR20240068070A (cg-RX-API-DMAC7.html)
CN (1) CN118043343A (cg-RX-API-DMAC7.html)
AU (1) AU2022355496A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232071A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003940A (cg-RX-API-DMAC7.html)
WO (1) WO2023050006A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
CN115943210A (zh) 2020-01-20 2023-04-07 中外制药株式会社 配体结合融合蛋白
AU2024407051A1 (en) 2023-12-18 2026-07-30 Genzyme Corporation Il-12 loss of potency muteins
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102884523B1 (ko) * 2018-10-03 2025-11-10 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
MX2022011676A (es) * 2020-03-23 2023-03-08 Zymeworks Bc Inc Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.

Also Published As

Publication number Publication date
EP4408870A4 (en) 2025-10-22
CN118043343A (zh) 2024-05-14
EP4408870A1 (en) 2024-08-07
US20240228567A1 (en) 2024-07-11
MX2024003940A (es) 2024-04-22
JP2024535925A (ja) 2024-10-02
CA3232071A1 (en) 2023-04-06
AU2022355496A1 (en) 2024-05-02
WO2023050006A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
JP7773991B2 (ja) マスクされたil12融合タンパク質及びその使用方法
JP7863602B2 (ja) 分離部分及びその使用方法
US20240228567A1 (en) Modified interleukin p40 subunit proteins and methods of use thereof
US20230227584A1 (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
US20240043535A1 (en) IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULES
CN112424228B (zh) 新型双特异性激动性4-1bb抗原结合分子
CN113677403B (zh) 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
JP7675083B2 (ja) 新規4-1bbl三量体含有抗原結合分子
WO2019086499A1 (en) Novel tnf family ligand trimer-containing antigen binding molecules
JP2020515541A (ja) 共刺激性tnf受容体に対する二重特異性抗原結合分子
WO2025133042A2 (en) Activatable fusion proteins and methods of use
HK40110021A (en) Modified interleukin p40 subunit proteins and methods of use thereof
HK40085919A (en) Masked il12 fusion proteins and methods of use thereof
US20250333542A1 (en) Interferon gamma variants and antigen binding molecules comprising these
HK40119034A (en) Interferon gamma variants and antigen binding molecules comprising these
KR20260030113A (ko) 항체 및 그의 용도
HK40075193A (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
HK40091599A (en) Immune activating fc domain binding molecules

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000